Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.54 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CIT | O14578 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994483 | 1.00 | BACE1 (0.57) | BACE1SMN1; SMN2NPC1RAB9AHDAC8 | |
| SCHEMBL24514045 | 0.88 | LNPEP (0.50) | BACE1SMN1; SMN2NPC1RAB9AHDAC8 | |
| SCHEMBL6665555 | 0.87 | KMT2A (0.65) | BACE1SMN1; SMN2RAB9AHDAC8ROCK2 | |
| SCHEMBL30452307 | 0.87 | KMT2A (0.65) | BACE1SMN1; SMN2RAB9AHDAC8ROCK2 | |
| SCHEMBL5158075 | 0.87 | BACE1 (0.53) | BACE1NPC1RAB9AHDAC8ROCK2 | |
| SCHEMBL5158068 | 0.87 | BACE1 (0.53) | BACE1NPC1RAB9AHDAC8ROCK2 | |
| SCHEMBL2312372 | 0.86 | BACE1 (0.63) | BACE1NPC1RAB9AHDAC8LTA4H | |
| SCHEMBL28279157 | 0.86 | BACE1 (0.63) | BACE1NPC1RAB9AHDAC8LTA4H | |
| SCHEMBL2312361 | 0.86 | BACE1 (0.63) | BACE1NPC1RAB9AHDAC8LTA4H | |
| SCHEMBL23466750 | 0.86 | RAB9A (0.60) | BACE1SMN1; SMN2NPC1RAB9AHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152664-B1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8367709-B2 | Dipeptide analogs as coagulation factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-08 | — | — | US | disclosed |
| EP-2152664-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | Brystol-Myers Squibb Company (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008157162-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | F11, TFPI, SERPINC1 | BACE1 641/4885SMN1; SMN2 3808/4885NPC1 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.